Press "Enter" to skip to content

AstraZeneca Revamp Covid-19 vaccine Accuracy Data

AstraZeneca issued revamped phase three trial data for its Covid-19 vaccine on Wednesday. The vaccine has been under rigorous scrutiny from the U.S. regarding its efficacy rates. Earlier, the company asserted that its Symptomatic efficacy rate is 79%, but after allegations, the company revised its accuracy data to a low figure.

The company now says its vaccine is 76% effective in protection against Symptomatic Cases of the virus. AstraZeneca’s Covid-19 vaccine new revamp has been the latest vaccine to be added into the framework of three effective vaccines. The updated report maintains that the dose is 100% effective against severe diseases and hospitalizations.

US Health officials criticized the company in recent times for maneuvering falsifying data in an effort to make the results appear more favorable. At that time, AstraZeneca CEO said that the results were based on a prespecified interim analysis and vowed to share updated data in the coming days.

Dr. Anthony Fauci interpreted the situation as an unfortunate event for those at AstraZeneca and said it was likely that the company issued a modified statement on the efficacy of its Covid-19 vaccine. “This is really what you call an unforced error because the fact is this is very likely a very good vaccine,” Fauci told ABC’s Robin Roberts on “Good Morning America” on Tuesday.

The findings recommend the vaccine is more effective in patients aged 65 and older than previously expected. AstraZeneca following the blatant criticism reiterated on Wednesday that the vaccine was well-tolerated among patients and no safety concerns were detected while inoculation of the vaccines.  AstraZeneca has been facing backlash in recent weeks over reports of blood clotting in conjunction with its Covid-19 vaccine. Such syndrome is approved and in use by dozen of countries around the world.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *